HomeCompareJNJ vs ALGN

JNJ vs ALGN: Dividend Comparison 2026

JNJ yields 2.14% · ALGN yields 1.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $9.1K in total portfolio value· pulled ahead in Year 6
10 years
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →
ALGN
ALGN
● Live price
1.20%
Share price
$166.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$130.06
Full ALGN calculator →

Portfolio growth — JNJ vs ALGN

📍 JNJ pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJNJALGN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JNJ + ALGN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JNJ pays
ALGN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
ALGN
Annual income on $10K today (after 15% tax)
$102.25/yr
After 10yr DRIP, annual income (after tax)
$110.55/yr
At 15% tax rate, JNJ beats the other by $3,926.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JNJ + ALGN for your $10,000?

JNJ: 50%ALGN: 50%
100% ALGN50/50100% JNJ
Portfolio after 10yr
$25.9K
Annual income
$2,439.97/yr
Blended yield
9.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ALGN right now

JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
ALGN
Analyst Ratings
24
Buy
7
Hold
2
Sell
Consensus: Buy
Price Target
$197.30
+18.7% upside vs current
Range: $140.00 — $220.00
Altman Z
4.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JNJ buys
8
ALGN buys
0
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJNJALGN
Forward yield2.14%1.20%
Annual dividend / share$5.20$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR28%0%
Portfolio after 10y$30.5K$21.4K
Annual income after 10y$4,749.88$130.06
Total dividends collected$15.6K$1.3K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$228.73$197.30

Year-by-year: JNJ vs ALGN ($10,000, DRIP)

YearJNJ PortfolioJNJ Income/yrALGN PortfolioALGN Income/yrGap
1$10,594$274.49$10,820$120.29$226.00ALGN
2$11,294$360.69$11,699$121.65$405.00ALGN
3$12,133$476.91$12,641$122.92$508.00ALGN
4$13,156$635.42$13,650$124.13$494.00ALGN
5$14,432$854.61$14,731$125.27$299.00ALGN
6← crossover$16,056$1,162.76$15,889$126.34+$167.00JNJ
7$18,175$1,604.53$17,128$127.36+$1.0KJNJ
8$21,009$2,252.68$18,455$128.31+$2.6KJNJ
9$24,911$3,229.73$19,876$129.21+$5.0KJNJ
10$30,458$4,749.88$21,398$130.06+$9.1KJNJ

JNJ vs ALGN: Complete Analysis 2026

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

ALGNStock

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Full ALGN Calculator →
📬

Get this JNJ vs ALGN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JNJ vs ABBVJNJ vs MRKJNJ vs PFEJNJ vs BMYJNJ vs LLYJNJ vs SCHDJNJ vs JEPIJNJ vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.